Fibroblast Growth Factor–21 ameliorates hepatic encephalopathy by activating the STAT3-SOCS3 pathway to inhibit activated hepatic stellate cells

Authors

  • Yeboah Kwaku Opoku Department of Biology Education, Faculty of Science Education, University of Education, Winneba, Ghana; Bio-pharmaceutical Laboratory, College of Life Sciences, Northeast Agricultural University, Harbin 150030, China. E-mail: kyeboah95@neau.edu.cn
  • Zhihang Liu Bio-pharmaceutical Laboratory, College of Life Sciences, Northeast Agricultural University, Harbin 150030, China
  • Justice Afrifa Department of Medical Laboratory Science, University of Cape Coast, Cape Coast, Ghana; Scientific Research Center, Second Affiliated Hospital of Harbin Medical University, Harbin, China
  • Asare Kwame Kumi Department of Protozoology, Institute of Tropical Medicine (NEKKEN), Nagasaki University, Japan; Department of Biomedical Sciences, University of Cape Coast, Ghana
  • Han Liu Bio-pharmaceutical Laboratory, College of Life Sciences, Northeast Agricultural University, Harbin 150030, China
  • George Ghartey-Kwansah Department of Biomedical Sciences, University of Cape Coast, Ghana
  • Harriet Koranteng Jiamusi University No. 148, Xuefu Road, Jiamusi, Heilongjiang, China
  • Xinghao Jiang Bio-pharmaceutical Laboratory, College of Life Sciences, Northeast Agricultural University, Harbin 150030, China
  • Guiping Ren Bio-pharmaceutical Laboratory, College of Life Sciences, Northeast Agricultural University, Harbin 150030, China
  • Deshan Li Bio-pharmaceutical Laboratory, College of Life Sciences, Northeast Agricultural University, Harbin 150030, China

DOI:

https://doi.org/10.17179/excli2020-1287

Keywords:

Acute liver failure (ALF), Thioacetamide (TAA), Pro-inflammatory cytokines, Fibrosis

Abstract

Neurological dysfunction, one of the consequences of acute liver failure (ALF), and also referred to as hepatic encephalopathy (HE), contributes to mortality posing challenges for clinical management. FGF21 has been implicated in the inhibition of cognitive decline and fibrogenesis. However, the effects of FGF21 on the clinical and molecular presentations of HE has not been elucidated. HE was induced by fulminant hepatic failure using thioacetamide (TAA) in male C57BL/6J mice while controls were injected with saline. For two consecutive weeks, mice were treated intraperitoneally with FGF21 (3 mg/kg) while controls were treated with saline. Cognitive, neurological, and activity function scores were recorded. Serum, liver, and brain samples were taken for analysis of CCL5 and GABA by ELISA, and RT qPCR was used to measure the expressions of fibrotic and pro-inflammatory markers. We report significant improvement in both cognitive and neurological scores by FGF21 treatment after impairment by TAA. GABA and CCL5, key factors in the progression of HE were also significantly reduced in the treatment group. Furthermore, the expression of fibrotic markers such as TGFβ and Col1 were also significantly downregulated after FGF21 treatment. TNFα and IL-6 were significantly reduced in the liver while in the brain, TNFα and IL-1 were downregulated. However, both in the liver and the brain, IL-10 was significantly upregulated. FGF21 inhibits CXCR4/CCL5 activation and upregulates the production of IL-10 in the damaged liver stimulating the production pro-inflammatory cytokines and apoptosis of hepatic stellate cells through the STAT3-SOCS3 pathway terminating the underlying fibrosis in HE.

Downloads

Published

2020-05-04

How to Cite

Opoku, Y. K., Liu, Z., Afrifa, J., Kumi, A. K., Liu, H., Ghartey-Kwansah, G., … Li, D. (2020). Fibroblast Growth Factor–21 ameliorates hepatic encephalopathy by activating the STAT3-SOCS3 pathway to inhibit activated hepatic stellate cells. EXCLI Journal, 19, 567–581. https://doi.org/10.17179/excli2020-1287

Issue

Vol. 19 (2020)

Section

Original articles

License

Authors who publish in this journal agree to the following terms:

  • The authors keep the copyright and grant the journal the right of first publication under the terms of the Creative Commons Attribution license, CC BY 4.0. This licencse permits unrestricted use, distribution and reproduction in any medium, provided that the original work is properly cited.
  • The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.
  • Because the advice and information in this journal are believed to be true and accurate at the time of publication, neither the authors, the editors, nor the publisher accept any legal responsibility for any errors or omissions presented in the publication. The publisher makes no guarantee, express or implied, with respect to the material contained herein.
  • The authors can enter into additional contracts for the non-exclusive distribution of the journal's published version by citing the initial publication in this journal (e.g. publishing in an institutional repository or in a book).

Most read articles by the same author(s)